Skip to content

    Aquestive Therapeutics (AQST) stock price & financials

    View AQST earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+30.4% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $13.54M
    $11.87M
    $8.72M
    $10.00M
    $12.81M
    -5.4%
    $13.02M
    +9.7%
    $14.45M
    +65.7%
    $13.82M
    +38.1%
    Strengthening
    Operating Profit
    -$8.29M
    -$13.58M
    -$19.36M
    -$11.37M
    -$11.48M
    -38.5%
    -$28.84M
    -112.4%
    -$4.20M
    +78.3%
    -$8.22M
    +27.7%
    Stable
    Net Profit
    -$11.51M
    -$17.05M
    -$22.93M
    -$13.55M
    -$15.45M
    -34.2%
    -$31.86M
    -86.8%
    -$8.06M
    +64.9%
    -$22.86M
    -68.8%
    Weakening
    EPS
    $-0.13
    $-0.24
    $-0.14
    $-0.14
    -7.7%
    $-0.07
    +70.8%
    $-0.18
    -28.6%
    Strengthening
    Other Income
    Interest
    $2.78M
    $2.78M
    $2.78M
    $2.78M
    $2.78M
    -0.0%
    $2.78M
    -0.0%
    $2.90M
    +4.3%
    $2.81M
    +0.9%
    Stable
    Depreciation
    Profit before Tax
    -$11.51M
    -$17.07M
    -$22.93M
    -$13.55M
    -$15.45M
    -34.2%
    -$31.86M
    -86.7%
    -$8.06M
    +64.9%
    -$22.86M
    -68.8%
    Weakening
    MarginsOPM
    -61.2%
    -114.4%
    -222.1%
    -113.7%
    -89.6%
    -46.4%
    -221.6%
    -93.6%
    -29.1%
    +86.9%
    -59.5%
    +47.6%
    Strengthening
    Tax
    0.0%
    0.1%
    0.0%
    0.0%
    0.0%
    0.0%
    -100.0%
    0.0%
    0.0%
    Weakening
    ReturnsROIC
    2.4%
    3.6%
    4.8%
    2.8%
    3.2%
    +34.2%
    6.7%
    +86.8%
    1.7%
    -64.9%
    4.8%
    +68.8%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$60.60M$49.33M$31.81M$28.02M$27.27M$23.87M$71.55M$121.17M$98.49M
    Short-Term Investments
    Total Current Assets$74.20M$68.31M$44.63M$47.26M$39.89M$40.97M$88.22M$149.27M$118.49M
    Net PP&E$12.21M$9.73M$10.32M$7.78M$9.30M$9.74M$8.98M$8.51M$11.91M
    Goodwill
    Intangibles$204.0K$153.0K$102.0K$51.0K$1.44M$1.28M$0$0
    Total Assets$86.85M$78.48M$62.88M$61.99M$57.07M$57.42M$101.42M$160.43M$132.10M
    LiabilitiesTotal Current Liabilities$32.95M$18.55M$21.10M$21.96M$39.53M$18.31M$18.86M$47.61M$16.48M
    Short-Term Debt$9.99M$32.0K
    Long-Term Debt$70.00M$51.50M$45.00M$45.00M$45.00M$55.00M
    Long-Term Leases$0$2.85M$1.95M$5.08M$5.40M$4.97M$4.34M$7.53M
    Total Liabilities$76.77M$84.60M$111.38M$144.13M$175.62M$163.91M$161.58M$194.09M$188.69M
    EquityCommon Stock & APIC$25.0K$34.0K$35.0K$41.0K$55.0K$69.0K$91.0K$122.0K$126.0K
    Retained Earnings-$61.38M-$130.47M-$186.26M-$256.80M-$311.21M-$319.08M-$363.21M-$447.00M-$477.92M
    Total Equity$10.08M-$6.12M-$48.50M-$82.13M-$118.55M-$106.49M-$60.16M-$33.66M-$56.59M
    HighlightsNet Cash / (Debt)$66.17M$43.46M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$12.99M-$60.21M-$45.46M-$32.98M-$9.82M-$6.38M-$35.76M-$52.43M-$45.37M
    Cash from Investing-$1.82M-$663.0K-$517.0K-$913.0K-$2.52M-$995.0K-$159.0K-$562.0K-$584.0K
    Cash from Financing$58.03M$49.60M$28.46M$30.11M$11.59M$3.97M$83.59M$102.62M$83.90M
    SummaryCapital Expenditure-$1.82M-$663.0K-$517.0K-$913.0K-$1.02M-$995.0K-$159.0K-$562.0K-$584.0K
    Free Cash Flow-$14.81M-$60.87M-$45.98M-$33.89M-$10.84M-$7.38M-$35.92M-$52.99M-$45.95M
    FCF Margin-22.0%-115.7%-100.3%-66.7%-22.7%-14.6%-62.4%-119.0%-85.0%

    Ratios